We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $178.98, moving +0.36% from the previous trading session. This change lagged the S&P 500's 1.27% gain on the day. Meanwhile, the Dow gained 1.25%, and the Nasdaq, a tech-heavy index, added 1.48%.
Heading into today, shares of the drugmaker had gained 7.03% over the past month, outpacing the Medical sector's loss of 2.58% and the S&P 500's loss of 4.37% in that time.
Investors will be hoping for strength from VRTX as it approaches its next earnings release. The company is expected to report EPS of $1.12, up 2.75% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $945.82 million, up 20.56% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.58 per share and revenue of $3.71 billion, which would represent changes of +12.25% and +21.69%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for VRTX. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 11.07% higher. VRTX is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, VRTX currently has a Forward P/E ratio of 38.93. This represents a premium compared to its industry's average Forward P/E of 27.08.
Investors should also note that VRTX has a PEG ratio of 1.73 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.92 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Vertex Pharmaceuticals (VRTX - Free Report) closed the most recent trading day at $178.98, moving +0.36% from the previous trading session. This change lagged the S&P 500's 1.27% gain on the day. Meanwhile, the Dow gained 1.25%, and the Nasdaq, a tech-heavy index, added 1.48%.
Heading into today, shares of the drugmaker had gained 7.03% over the past month, outpacing the Medical sector's loss of 2.58% and the S&P 500's loss of 4.37% in that time.
Investors will be hoping for strength from VRTX as it approaches its next earnings release. The company is expected to report EPS of $1.12, up 2.75% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $945.82 million, up 20.56% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.58 per share and revenue of $3.71 billion, which would represent changes of +12.25% and +21.69%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for VRTX. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 11.07% higher. VRTX is holding a Zacks Rank of #2 (Buy) right now.
Digging into valuation, VRTX currently has a Forward P/E ratio of 38.93. This represents a premium compared to its industry's average Forward P/E of 27.08.
Investors should also note that VRTX has a PEG ratio of 1.73 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.92 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 82, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.